Concepedia

Alberto Odio

AO

Statistics

Publications

6

Citations

2.2K

H-Index

6

Active since

1986

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Pontificia Universidad Católica de Chile

Emory University

Stellenbosch University

Alberto Odio is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacotherapy, medicine, and osteoporosis in women.

Publications per year

1986–2024

6

Publications

6

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.8K citations · Full text

, , +17

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

Michael R. McClung, Michelle L. O’Donoghue, Socrates E. Papapoulos et al. · The Lancet Diabetes & Endocrinology · 2019 · 169 citations

, , +10

Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent <i>Clostridioides difficile</i> Infection

Matthew Sims, Sahil Khanna, Paul Feuerstadt et al. · JAMA Network Open · 2023 · 81 citations · Full text

, , +13

Effects of Odanacatib on BMD and Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With Alendronate: A Randomized Placebo-Controlled Trial

Sydney Lou Bonnick, Tobias De Villiers, Alberto Odio et al. · The Journal of Clinical Endocrinology & Metabolism · 2013 · 59 citations

, , +14

Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial

Heather Platt, Christopher Bruno, Erik Buntinx et al. · The Lancet Infectious Diseases · 2024 · 53 citations

, , +16

1–5 of 6